Stockreport

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline [Yahoo! Finance]

T. Rowe Price Group, Inc.  (TROW) 
Last t. rowe price group, inc. earnings: 4/28 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: trow.client.shareholder.com
PDF This capital infusion will accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV). The funds will also support the progression of [Read more]